THE C-REACTIVE PROTEIN ACCORDING TO LUNG INVOLVEMENT OF COVID-19 PATIENTS AT VERY HIGH ALTITUDE
Proteína C reactiva en COVID-19 en alta altitud
DOI:
https://doi.org/10.52428/20756208.v9i21.1111Keywords:
COVID-19, C-reactive protein, CO-RADS reporting system, prognosisAbstract
Introduction
The protein C-reactive is an important immunological marker due to its sensitivity to stimulate inflammation and or infections, it is necessary to study its role in the lung compromise and the evolution of COVID-19 disease. The objective of the present study is to determine the behavior of C-Reactive Protein according to lung involvement, in patients with a positive diagnostic of COVID-19 in the Hospital del Norte in El Alto, from 2021.
Material and method
It is a study which is characterize of observations, explanations, transversal, retrospective, due to a random simple sampling of 196 patients with a diagnosis of pneumonia and a positive RT-PCR test. There was a statistical analysis performed by the test of “chi cuadrado” where the variable depends on a report CORADS (compromise lung) and the independent variable is the protein C-reactive. Therefore, it can be calculate the frequency of variables: sex, age, type of relation between the age, PCR and CORADS and relation between the discharge types.
Results
196 subjects with the diagnostic of pneumonia and a positive RT-PCR were studied. There were found statistically a significance concentration between C-reactive protein and lung compromise (p = 0.000 < 0.05).
Discussion
The present study showed that there is a positive association between C - reactive protein concentrations and lung involvement. In view of the p-value obtained (p=0.01 < α=0.05), the existence of a statistical dependence between pulmonary involvement and the concentrations of C-Reactive protein is evident, the pulmonary involvement reported by the CORAD system varies in relation to the concentration of C-Reactive Protein
Keywords: COVID-19, CRP, CORADS.
Downloads
References
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA [Internet]. 7 de abril de 2020 [citado 20 de septiembre de 2023];323(13):1239-42. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32091533/
https://doi.org/10.1001/jama.2020.2648
PMid:32091533
Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol 2020 176 [Internet]. 19 de marzo de 2020 [citado 22 de septiembre de 2023];17(6):613-20. Disponible en: https://www.nature.com/articles/s41423-020-0400-4
https://doi.org/10.1038/s41423-020-0400-4
PMid:32203189 PMCid:PMC7091888
Cecconi M, Forni G, Mantovani A. Ten things we learned about COVID-19. Intensive Care Med. 2020 Aug;46(8):1590-1593. doi: 10.1007/s00134-020-06140-0
https://doi.org/10.1007/s00134-020-06140-0
PMid:32504103 PMCid:PMC7273118
Del Rio, C., & Malani, P. N. (2020). COVID-19-New Insights on a Rapidly Changing Epidemic. JAMA, 323(14), 1339-1340. https://doi.org/10.1001/jama.2020.3072
https://doi.org/10.1001/jama.2020.3072
PMid:32108857
Penha D, Pinto EG, Matos F, Hochhegger B, Monaghan C, Taborda-Barata L, et al. CO-RADS: Coronavirus Classification Review. J Clin Imaging Sci [Internet]. 2021 [citado 22 de septiembre de 2023];11(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/33767901/
https://doi.org/10.25259/JCIS_192_2020
PMid:33767901 PMCid:PMC7981938
Wanderley F. Serie Reflexiones sobre la Pandemia en Bolivia No 3 LOS IMPACTOS SOCIALES Y PSICOLÓGICOS DEL COVID-19 EN BOLIVIA. [citado 20 de septiembre de 2023]; Disponible en: http://www.iisec.ucb.edu.bo/video-categoria/seminarios-y-conferencias
Ministerio de Salud y Deportes de Bolivia - GOBIERNO DECLARA EMERGENCIA SANITARIA A NIVEL NACIONAL ANTE INCREMENTO DE CASOS COVID-19 EN EL PAÍS [Internet]. [citado 25 de marzo de 2024]. Disponible en: https://www.minsalud.gob.bo/6360-gobierno-declara-emergencia-sanitaria-a-nivel-nacional-ante-incremento-de-casos-covid-19-en-el-pais
EL ALTO Estudio con información estadística, descriptiva y analítica sobre las condiciones, oportunidades e institucionalidad de la población y la ciudad. Disponible en : https://searchworks.stanford.edu/view/9426323
Vaquero-Roncero LM, Sánchez-Barrado E, Escobar-Macias D, Arribas-Pérez P, González de Castro R, González-Porras JR, Sánchez-Hernandez MV; COVID Working Group. C-Reactive protein and SOFA scale: A simple score as early predictor of critical care requirement in patients with COVID-19 pneumonia in Spain. Rev Esp Anestesiol Reanim (Engl Ed). 2021 Nov;68(9):513-522. doi: 10.1016/j.redare.2020.11.008.
https://doi.org/10.1016/j.redare.2020.11.008
PMid:34743905 PMCid:PMC8568297
Fink MP. The prevention and treatment of sepsis: Is interleukin-6 a drug target or a drug? Crit Care Med [Internet]. marzo de 2006 [citado 21 de marzo de 2024];34(3):919-21. Disponible en: https://journals.lww.com/ccmjournal/fulltext/2006/03000/the_prevention_and_treatment_of_sepsis__is.62.aspx
https://doi.org/10.1097/01.CCM.0000203108.60429.DF
PMid:16505686
Fauci A, Langford C. Harrison's Rheumatology. 2010 [citado 21 de marzo de 2024];361. Disponible en: https://books.google.com/books/about/Harrison_s_Rheumatology_Second_Edition.html?hl=es&id=kKtbeHwxDb8C
Abbas AK, Lichtman AH, Pillai S. Chapter 8: Lymphocyte Development and Antigen Receptor Gene Rearrangement . Preview Cell Mol Immunol [Internet]. 2021 [citado 21 de marzo de 2024];187-216. Disponible en: https://www.elsevier.com/books/cellular-and-molecular-immunology/abbas/978-0-323-75748-5
Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol [Internet]. 1995 [citado 21 de marzo de 2024];102(1):217-23. Disponible en: https://pubmed.ncbi.nlm.nih.gov/7554393/
https://doi.org/10.1111/j.1365-2249.1995.tb06659.x
PMid:7554393 PMCid:PMC1553348
Scheller J, Grötzinger J, Rose-John S. Updating interleukin-6 classic- and trans-signaling. Signal Transduct [Internet]. 1 de agosto de 2006 [citado 21 de marzo de 2024];6(4):240-59. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/sita.200600086
https://doi.org/10.1002/sita.200600086
Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med [Internet]. 1966 [citado 20 de septiembre de 2023];123(2):365-78. Disponible en: https://pubmed.ncbi.nlm.nih.gov/4379352/
https://doi.org/10.1084/jem.123.2.365
PMid:4379352 PMCid:PMC2138142
Gryska K, Stupianek A, Laciak M, Gorny A, Mackiewicz K, Baumann H, et al. Inflammatory cytokines controlling branching of N-heteroglycans of acute phase protein. Adv Exp Med Biol. 1995;376:239-45.
https://doi.org/10.1007/978-1-4615-1885-3_26
PMid:8597254
Gershow D, Kim S BN et al. C-reactive protein binds to apoptotic cells, protects the cell from assembly to the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. 2000 [citado 20 de septiembre de 2023]. p. 1353-63 C-reactive protein binds to apoptotic cells, protects the cell from assembly to the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. Disponible en: https://rupress.org/jem/article-pdf/192/9/1353/1701865/000697.pdf
https://doi.org/10.1084/jem.192.9.1353
PMid:11067883 PMCid:PMC2193350
Pepys, M. B., & Hirschfield, G. M. (2003). C-reactive protein: a critical update. The Journal of clinical investigation, 111(12), 1805-1812. https://doi.org/10.1172/JCI18921
https://doi.org/10.1172/JCI18921
PMid:12813013 PMCid:PMC161431
Verma, S., Li, S. H., Badiwala, M. V., Weisel, R. D., Fedak, P. W., Li, R. K., Dhillon, B., & Mickle, D. A. (2002). Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 105(16), 1890-1896. https://doi.org/10.1161/01.cir.0000015126.83143.b4
https://doi.org/10.1161/01.CIR.0000015126.83143.B4
PMid:11997273
Baez AM, Ríos-González CM. Thrombotic arterial complications in patients hospitalized for COVID-19 in a regional hospital in Paraguay. Rev del Nac. 1 de junio de 2023;15(1):47-58. Disponioble en: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S2072-81742023000100047
https://doi.org/10.18004/rdn2023.jun.01.047.058
González Del Castillo, J., Jacob, J., García-Lamberechts, E. J., Piñera Salmerón, P., Alquézar-Arbé, A., Llorens, P., Jiménez, S., Quero Espinosa, F. B., Aguiló, S., Gil-Rodrigo, A., Fernández Alonso, C., Burillo-Putze, G., Espinosa Fernández, B., Suero Méndez, C., Iglesias Vela, M., Quero Motto, E., Hong Cho, J. U., Llopis, F., Marrón, R., Gayoso Martín, S., Red de investigación SIESTA (2022). Sociodemographic characteristics, comorbidity, and baseline functional status of older patients treated in emergency departments during the COVID-19 pandemic and associations with mortality: an analysis based on the EDENCOVID cohort. Sociodemografía, comorbilidad y situación funcional basal de los pacientes mayores atendidos en urgencias durante la pandemia de COVID y su relación con la mortalidad: análisis a partir de la cohorte EDEN-Covid. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, 34(6), 428-436. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36625692/
Pusineri Escobar P, González-Gómez M, Barrios I, Torales J, Pusineri Escobar P, González-Gómez M, et al. Mortalidad en adultos con COVID-19: experiencia de la Unidad de Cuidados Intensivos de un Hospital de Tercer Nivel de Paraguay. Med clínica y Soc [Internet]. 1 de enero de 2023 [citado 14 de marzo de 2024];7(1):5-10. Disponible en: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S2521-22812023000100005&lng=en&nrm=iso&tlng=es
https://doi.org/10.52379/mcs.v7i1.272
Palacio Mejía LS, Wheatley Fernández JL, Ordoñez Hernández I, López Ridaura R, Lopez-Gatell Ramirez H, Hernandez Avila M, et al. Estimación del exceso de mortalidad por todas las causas durante la pandemia del Covid-19 en México. Salud Publica Mex [Internet]. 26 de febrero de 2021 [citado 25 de marzo de 2024];63(2, Mar-Abr):211-24. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34098600/
https://doi.org/10.21149/12225
PMid:34098600
Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob [Internet]. 15 de mayo de 2020 [citado 13 de marzo de 2024];19(1):1-7. Disponible en: https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-020-00362-2
https://doi.org/10.1186/s12941-020-00362-2
PMid:32414383 PMCid:PMC7227180
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alejandra Regina Maceda Maidana
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.